Capital Advisors Ltd’s Prelude Therapeutics PRLD Stock Holding History

Capital Advisors Ltd’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-33	Closed	–	–	1547
2022 Q3	$0	Buy	33 +22	+200%	+$148	﹤0.01%	1455
2022 Q2	$0	Buy	+11	New	+$56	﹤0.01%	1254

Other funds holding PRLD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital Advisors Ltd's PRLD Position: Q4 2022 in Review

Capital Advisors Ltd sold out of Prelude Therapeutics (PRLD) in Q4 2022, closing a stake of 33 shares.

Capital Advisors Ltd first reported a position in PRLD in Q2 2022 and held it in 2 quarters. The position peaked at $0 in Q3 2022. 60 funds tracked by Wall St. Rank hold PRLD as of Q4 2022.

Capital Advisors Ltd reported no remaining Prelude Therapeutics position as of Q4 2022 after selling out during the quarter.
Capital Advisors Ltd sold 33 Prelude Therapeutics shares in Q4 2022.
Capital Advisors Ltd first reported a position in Prelude Therapeutics in Q2 2022 and held it in 2 quarters.
Capital Advisors Ltd's Prelude Therapeutics position peaked at $0 in Q3 2022.
60 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2022.

Based on Capital Advisors Ltd's 13F filing for Q4 2022, filed 7 Feb 2023.